Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

As part of the agreement, Celltrion acknowledged that the denosumab patents it challenged were valid and infringed by the company’s biosimilar candidates in the U.S. The settlement appears to ...

Taken alongside Prolia/Xgeva, the brands account for well over 40% of Amgen's current revenues. Other companies working on biosimilar versions of denosumab include Samsung Bioepis, Celltrion, and ...

The report also discusses the spurt of Stelera biosimilar approvals in late 2024. FDA approval of two biosimilars to Prolia (denosumab) and a biosimilar to Xolair (omalizumab) are in the works, ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE ...

Denosumab may reduce fracture risk, but increase cardiovascular risks in patients on dialysis. Denosumab may reduce fracture risk better than oral bisphosphonates for treatment of osteoporosis in ...

Patients were initially randomized 1:1 to receive either CT-P41 or US-denosumab (60 mg subcutaneous injection at weeks 0, 26, and 52). In the second treatment period, patients on US-denosumab were ...

Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 65% phase transition success ...

“Denosumab helps maintain bone strength ... of this medicine for people with osteoporosis is that it’s an injection they can give to themselves or can be given by a caregiver.

3759.HK Pharmaron Beijing Co., Ltd.